Using hyperbaric oxygen to prevent lung damage from breast cancer radiation therapy
Official title: Study on the Effectiveness and Safety of Hyperbaric Oxygen Therapy for Preventing Radiation Pneumonitis Caused by Radiotherapy and Chemotherapy of Breast Cancer
Run by Guangdong Provincial People's Hospital · NCT05189496 · Data updated 2026-11-12
This study is testing if hyperbaric oxygen therapy can help prevent lung damage in breast cancer patients receiving radiation treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 380 (estimated) |
| Sponsor | Guangdong Provincial People's Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | March 1, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | February 12, 2025 |
| Trial ID | NCT05189496 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are breast cancer patients aged 18 to 70 who have undergone radical treatment and are receiving adjuvant chemotherapy followed by radiotherapy.
✕Probably not a fit
Patients with severe lung diseases or those who have experienced acute radiation lung injury may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of hyperbaric oxygen therapy to reduce the incidence of radiation pneumonitis in breast cancer patients undergoing radiotherapy. It aims to enroll 380 participants who will be randomly assigned to receive either hyperbaric oxygen therapy or standard care after their radiotherapy treatment. The study will evaluate the safety of the therapy and its potential to improve patients' quality of life and long-term survival outcomes by promoting tissue repair and reducing inflammation. The approach focuses on enhancing vascular function and reducing fibrosis associated with radiation injury.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the risk of radiation pneumonitis and improve the quality of life for breast cancer patients.
How similar studies have gone: While hyperbaric oxygen therapy has shown promise in treating radiation injuries in other contexts, this specific application in breast cancer patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Volunteer to participate and sign informed consent in writing. (2) Past pathological diagnosis of breast cancer followed by radical treatment/surgery for breast cancer, followed by adjuvant chemotherapy followed by radiotherapy. (3) Excluding patients with simple neck lymph node recurrence and patients with distant metastases. (4) There is no secondary malignant tumor in other parts. (5) Age at entry ≥ 18 years old and ≤ 70 years old, both male and female. (6) The Eastern Cooperative Oncology Group (ECOG) has a performance status score of 0 or 1. (7) The expected survival period is ≥2 years. (8) There was no acute radiation lung injury in chest CT examination before and after radiotherapy Exclusion Criteria: * (1) Contraindications to hyperbaric oxygen therapy: lung disease (severe chronic obstructive airway disease, bullous lung disease, acute or chronic lung infection, uncontrolled asthma, untreated pneumothorax), in the past History of ear surgery, middle ear disease (eustachian tube dysfunction, recurrent dizziness), eye disease (retinal detachment). (2) Have received hyperbaric oxygen therapy in the past. (3) Radiation pneumonia had occurred at the time of enrollment or before receiving hyperbaric oxygen therapy. (4) Women who are pregnant or breastfeeding. (5) Patients who have not completed comprehensive breast cancer treatment due to disease progression, intolerable side effects, abandonment of treatment and other reasons. (8) Patients who need mechanical ventilation support. (9) Patients who cannot follow and understand simple commands. (10) Patients with disorientation and mental disorders.
Where it's running
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Kun Wang
- Email: gzwangkun@126.com
- Phone: 13922118086
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
4DCT-guided functional lung avoidance radiotherapy to spare high-function lung
This study will test whether using 4DCT-derived lung ventilation maps to guide radiotherapy can better spare high-function lung in adults receiving thoracic IMRT or SBRT for lung cancer.
-
Analyzing lung inflammation signals in cancer patients treated with radiotherapy
This study is trying to understand the lung inflammation that some cancer patients experience after radiation treatment by looking closely at the cells involved.
-
Impact of Radiation Therapy on Lung Function in Breast Cancer Patients
This study is testing how radiation therapy affects lung function in breast cancer patients to help create better ways to prevent and treat lung problems after their treatment.
-
SPECT-guided radiation that spares well-functioning lung during curative lung cancer treatment
This trial will test whether using perfusion SPECT/CT to guide radiation plans that avoid highly functional lung reduces radiation-related lung damage for adults receiving curative chemo-radiation for lung cancer.
-
Using inhaled steroids to prevent radiation pneumonitis in lung cancer patients
This study is testing if inhaled steroids can help lung cancer patients avoid or lessen lung problems caused by radiation treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.